Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset

BACKGROUND: Autoimmune thyroid disease (AITD) occurs in 40%–50% of alemtuzumab-treated persons with multiple sclerosis (pwMS), most of whom will develop Graves’ Disease (GD). OBJECTIVE: To explore contributory factors for alemtuzumab-related AITD in pwMS. METHODS: A retrospective patient chart revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Siew Mei, Dillon, Mary, Crowley, Rachel K, McGuigan, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307483/
https://www.ncbi.nlm.nih.gov/pubmed/32612846
http://dx.doi.org/10.1177/2055217320933928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307483/
https://www.ncbi.nlm.nih.gov/pubmed/32612846
http://dx.doi.org/10.1177/2055217320933928

Ejemplares similares